Tenax Therapeutics

Historical price data

Tenax Therapeutics is on a mission to address the critical unmet need in PH-HFpEF, the most common form of pulmonary hypertension globally. Its strategy centers on the targeted repurposing of levosimendan, developing an oral formulation (TNX-103) for chronic use based on the drug's well-known safety profile and promising early clinical data in PH-HFpEF. The company is led by a veteran management team with deep cardiovascular development experience and is currently executing a Phase 3 clinical program designed to derisk the path to potential regulatory approval.

Targeted repurposing and reformulation of established drugs, specifically levosimendan, for chronic cardiovascular conditions with high unmet need.

The PH-HFpEF field has no approved therapies and is marked by past failures of major pharma programs. Tenax's oral levosimendan, with positive Phase 2 data, is among the most advanced candidates, facing competition mainly from standard of care and earlier-stage investigational drugs.